Augmedix ( (AUGX) ) has provided an update.
Commure, a healthcare technology company, has successfully acquired Augmedix, which will now function as its wholly-owned subsidiary. The merger, approved by Augmedix stockholders, offers them $2.35 per common share. Post-merger, Augmedix’s common stock has been suspended from trading on Nasdaq and will be delisted. This strategic move aims to amplify Commure’s impact by utilizing Augmedix’s expertise in clinical documentation, with the vision to enhance healthcare workflows and patient care through AI-powered solutions.
See more data about AUGX stock on TipRanks’ Stock Analysis page.
